Rivastigmine Tartrate Capsule
Product Images NDC 62332-063

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 62332-063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsules (Rivastigmine 1 5mg 30 Bottle)

Rivastigmine Tartrate Capsules are available in a 30 capsule pack. The NDC number for these capsules is 62332-063-30 and the GTIN number is 00362332063307. There are some unclear and non-English characters in the text.*

FDA Label Image

30 Capsules (Rivastigmine 3mg 30 Bottle)

FDA Label Image

30 Capsules (Rivastigmine 4 5mg 30 Bottle)

FDA Label Image

30 Capsules (Rivastigmine 6mg 30 Bottle)

FDA Label Image

Figure 1 (Rivastigmine Fig1)

FDA Label Image

Figure 2 (Rivastigmine Fig2)

FDA Label Image

Figure 3 (Rivastigmine Fig3)

FDA Label Image

Figure 4 (Rivastigmine Fig4)

This is a table or graph presenting the mean (+/- SEM) change from baseline in AADAS-cog rating during treatment over a period of 26 weeks. It seems to be related to clinical improvement or decline.*

FDA Label Image

Figure 5 (Rivastigmine Fig5)

The information provided seems to be a chart or graph that shows the cumulative percentage of patients in different treatment groups and the change in ADAS-cog scores from baseline. The treatment groups are labeled as TeamentGrop, Placebo, t-4mgly, and 612mgidy. The chart also shows the change in ADAS-cog scores at different levels, ranging from -20 to +25. It is not clear what this chart represents without further context.*

FDA Label Image

Figure 6 (Rivastigmine Fig6)

The text represents a chart or graph showing the percentage of patients and their improvement level with different dosages of a drug compared to placebo using CIBIC-Plus rating as a measure. The dosages vary from 0 to 12 mg, and the improvement level ranges from markedly worse to markedly improved.*

FDA Label Image

Figure 8 (Rivastigmine Fig8)

FDA Label Image

Figure 7 (Rivastigmine Figure7)

FDA Label Image

Structure (Rivastigmine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.